Literature DB >> 17485365

p53 in breast cancer: mutation and countermeasures.

Sumit Kumar1, Vijay Walia, Maria Ray, Randolph C Elble.   

Abstract

p53 is the primary arbiter of the mammalian cell's response to stress, the governor of life and death. It is the nexus upon which signals converge from an array of sensors that detect damage to DNA or to the mitotic spindle or the cytoskeleton, hypoxia, cell detachment, growth factor deprivation, oncogene expression and other forms of stress. Depending on the type, intensity and duration of the signals, p53 in turn transactivates batteries of genes specifying cell cycle arrest, DNA repair, apoptosis, or other anti-neoplastic functions. At the same time, p53 represses anti-apoptotic and survival functions. The type, intensity and duration of signaling dictate the sequellae. While this response is combinatorial, the frequent perturbation of p53 function in a wide spectrum of cancers attests to its central role in the suppression of neoplasia. As our understanding of regulation by and of p53 has deepened, many possibilities have been suggested for re-establishing p53 or its effectors in tumor cells. This review will briefly summarize the role of p53 mutations in the etiology and treatment of breast cancer and then consider the wide array of strategies being developed to re-establish p53 function in tumor cells.

Entities:  

Mesh:

Year:  2007        PMID: 17485365     DOI: 10.2741/2378

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  7 in total

1.  Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Authors:  Yayun Liang; Cynthia Besch-Williford; Indira Benakanakere; Philip E Thorpe; Salman M Hyder
Journal:  Breast Cancer Res Treat       Date:  2010-03-27       Impact factor: 4.872

Review 2.  Challenges to defining a role for progesterone in breast cancer.

Authors:  Carol A Lange
Journal:  Steroids       Date:  2007-12-28       Impact factor: 2.668

Review 3.  Progesterone and breast cancer.

Authors:  Carol A Lange; Douglas Yee
Journal:  Womens Health (Lond)       Date:  2008-03

4.  The expression of PCNA, c-erbB-2, p53, ER and PR as well as atypical hyperplasia in tissues nearby the breast cancer.

Authors:  Zongliang Jia; Wei Zhao; Lin Fan; Wei Sheng
Journal:  J Mol Histol       Date:  2011-11-05       Impact factor: 2.611

Review 5.  Heat shock proteins in animal neoplasms and human tumours--a comparison.

Authors:  Mariarita Romanucci; Tania Bastow; Leonardo Della Salda
Journal:  Cell Stress Chaperones       Date:  2008-03-12       Impact factor: 3.667

Review 6.  Antibody targeting of phosphatidylserine for the detection and immunotherapy of cancer.

Authors:  Olivier Belzile; Xianming Huang; Jian Gong; Jay Carlson; Alan J Schroit; Rolf A Brekken; Bruce D Freimark
Journal:  Immunotargets Ther       Date:  2018-01-23

7.  A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts.

Authors:  Yayun Liang; Benford Mafuvadze; Cynthia Besch-Williford; Salman M Hyder
Journal:  Breast Cancer (Dove Med Press)       Date:  2018-03-22
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.